Global ADC Contract Manufacturing Market SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)
Global ADC Contract Manufacturing Market is segmented By Stage of Development(Phase I, Phase II, Phase III), By Process Component(Antibody, HPAPI / Cytotoxic Payload, Conjugation / Linker, Fill / Finish), By Target Indication (Solid Tumors, Hematological Tumors, Others), By Antibody Generation(Second Generation, Third Generation, Fourth Generation, Next Generation), By Antibody Origin (Humanized, Chimeric, Murine, Others), By Type of Linker (Maleimide, SMCC, Tetrapeptide-based linker, Valine-citrulline, Others), By End User (Pharmaceutical Companies, Biotechnology Companies - 30%, Academic & Research Institutes, Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa). The report offers the value (in USD Billion) for the above-mentioned segments.
Global ADC Contract Manufacturing Market Size
Market Size in USD
CAGR13.2%
| Study Period | 2024 - 2031 |
| Base Year of Estimation | 2023 |
| CAGR | 13.2% |
| Market Concentration | High |
| Major Players | AbbVie Contract Manufacturing, Abzena, CARBOGEN AMCIS, Catalent Pharma Solutions, Cerbios-Pharma |
please let us know !
Global ADC Contract Manufacturing Market Analysis
The Global ADC Contract Manufacturing Market is estimated to be valued at USD 1.83 Billion in 2024 and is expected to reach USD 4.30 Billion by 2031, growing at a compound annual growth rate (CAGR) of 13.2% from 2024 to 2031. Several factors are contributing to the growth of this market such as rising demand for ADC for cancer treatment, increasing R&D investment for the development of novel ADC, and growing collaboration between pharmaceutical companies and contract manufacturing organizations.
The market trend in the Global ADC Contract Manufacturing industry suggests lucrative opportunities for contract manufacturing organizations to capitalize on. As big pharmaceutical companies continue outsourcing their ADC manufacturing needs, CMOs with requisite expertise, infrastructure and capabilities stand to benefit immensely. Additionally, as newer ADC molecules gain regulatory approvals, the demand for extensive manufacturing capabilities is poised to drive partnerships between drug developers and CMOs.